A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

NCT06445400 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: BL-M07D1
DRUG: Pertuzumab
DRUG: Docetaxel

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]